Aptorum Group Limited (NASDAQ:APM) Sees Large Increase in Short Interest

Aptorum Group Limited (NASDAQ:APMGet Free Report) was the target of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,600 shares, an increase of 70.4% from the October 15th total of 2,700 shares. Based on an average daily volume of 19,700 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the company’s stock are short sold.

Hedge Funds Weigh In On Aptorum Group

An institutional investor recently bought a new position in Aptorum Group stock. Murchinson Ltd. bought a new stake in Aptorum Group Limited (NASDAQ:APMFree Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned approximately 0.27% of Aptorum Group as of its most recent SEC filing. Hedge funds and other institutional investors own 3.80% of the company’s stock.

Aptorum Group Stock Performance

Shares of APM stock opened at $1.20 on Wednesday. Aptorum Group has a 12 month low of $1.20 and a 12 month high of $17.49. The firm has a fifty day simple moving average of $1.97 and a two-hundred day simple moving average of $3.33.

Aptorum Group Company Profile

(Get Free Report)

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.

Further Reading

Receive News & Ratings for Aptorum Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptorum Group and related companies with MarketBeat.com's FREE daily email newsletter.